Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133921 | 0.76 | GRM5 (0.57) | GRM5KDM4EACACBKCNH2 | |
| SCHEMBL30468202 | 0.72 | FFAR1 (0.47) | KDM4EFFAR1KCNH2 | |
| SCHEMBL2466535 | 0.72 | FFAR1 (0.47) | KDM4EFFAR1KCNH2 | |
| SCHEMBL27165265 | 0.72 | GRM5 (0.49) | GRM5FFAR1 | |
| SCHEMBL24078823 | 0.68 | NNMT (0.36) | GRM5KDM4EACACBNNMT | |
| SCHEMBL29038518 | 0.68 | NQO2 (0.39) | GRM5FFAR1 | |
| SCHEMBL12424795 | 0.67 | GRM5 (0.55) | GRM5KCNH2 | |
| SCHEMBL24436467 | 0.66 | NNMT (0.34) | KDM4EACACBNNMT | |
| SCHEMBL24078822 | 0.65 | PDE2A (0.47) | GRM5KDM4ENNMT | |
| SCHEMBL2079638 | 0.65 | NQO1 (0.43) | KDM4ENNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | GRM5 270/4885KDM4E 3364/4885FFAR1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.